Jacobs Levy Equity Management Inc. Has $1.07 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Jacobs Levy Equity Management Inc. lessened its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 101,397 shares of the company's stock after selling 551,651 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.10% of ARS Pharmaceuticals worth $1,070,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $73,000. BNP Paribas Financial Markets acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth about $75,000. Compass Capital Corp MA ADV bought a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at about $106,000. Teacher Retirement System of Texas acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at about $122,000. Finally, Freestone Grove Partners LP acquired a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $132,000. Institutional investors own 68.16% of the company's stock.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of analyst reports. Scotiabank began coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock traded up $0.07 during trading hours on Tuesday, hitting $14.33. The company had a trading volume of 1,544,411 shares, compared to its average volume of 1,234,677. ARS Pharmaceuticals, Inc. has a one year low of $7.55 and a one year high of $18.51. The firm has a market cap of $1.41 billion, a PE ratio of -28.10 and a beta of 0.84. The firm has a 50-day moving average of $13.38 and a 200 day moving average of $12.86.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. As a group, research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares of the company's stock, valued at $107,744. The trade was a 56.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Laura Shawver sold 50,002 shares of the stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares in the company, valued at $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,602 shares of company stock valued at $1,311,041 in the last quarter. Company insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.